LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

62-LB: Quantifying Insulin-Mediated and Noninsulin Mediated Glucose Disposal during Exercise in Patients with Type 1 Diabetes

Photo from wikipedia

Introduction: Glycemic control during exercise is challenging for people with type 1 diabetes. Better quantification of insulin dynamics at different exercise intensities and across insulin loading conditions is necessary for… Click to show full abstract

Introduction: Glycemic control during exercise is challenging for people with type 1 diabetes. Better quantification of insulin dynamics at different exercise intensities and across insulin loading conditions is necessary for accurate insulin dosing during exercise. Methods: Twenty seven participants with type 1 diabetes were evaluated during 3 separate 10-hour fasting aerobic exercise studies with low, medium, and high levels of insulin infusion (100%, 150%, and 300% of basal rate) across two exercise arms: moderate (40-45% of VO2 max), and intense (60-65% of VO2 max) exercise. Glucose levels were clamped during a 3-hour run-in period, followed by 45 minutes of exercise on a treadmill. 6,6-2H2-dideuterated glucose was infused to match endogenous glucose production during the entire trial. Glucose tracer data were fitted to a two-compartment ODE model, solved via Bayesian inference. We intend to quantify insulin and non-insulin mediated disposal of glucose by observing the rate of disposal (Rd) across different rates of insulin infusion in each exercise arm. Results: Area under the curve (AUC) of Rd during 45 minutes of moderate exercise increased by 0.084 mmol/L for every percent increase in baseline insulin infusion rate (95% CI=0.064-0.104, p Conclusion: Results indicate Rd is substantial during exercise but that the difference in glucose uptake during aerobic exercise at 40-45% VO2 max may be comparable with 60-65% VO2 max. Disclosure T.P. Nguyen: None. P.G. Jacobs: Stock/Shareholder; Self; Pacific Diabetes Technologies. J.R. Castle: Advisory Panel; Self; Novo Nordisk Inc., Zealand Pharma A/S. Consultant; Self; Dexcom, Inc. Research Support; Self; Dexcom, Inc., Xeris Pharmaceuticals, Inc. L.M. Wilson: None. D. Branigan: None. V. Gabo: None. B. Senf: None. F.H. Guillot: None. J. El Youssef: None. Funding National Institutes of Health

Keywords: none; disposal; insulin; type diabetes; vo2 max; exercise

Journal Title: Diabetes
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.